Hypertension, white matter change and response to cholinesterase inhibitors in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 20, Issue 7, 2005, Pages 623-628

  Connelly, Peter J ^a   Prentice, Neil P ^a   Fowler, Kenneth G ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b PERTH ROYAL INFIRMARY   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Hypertension; Response; White matter lesions

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN DISEASE; BRAIN FUNCTION; CIGARETTE SMOKING; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DETERIORATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MENTAL TEST; MINI MENTAL STATE EXAMINATION; MULTIVARIATE ANALYSIS OF VARIANCE; OUTPATIENT; PATIENT CODING; POPULATION RESEARCH; RATING SCALE; RETROSPECTIVE STUDY; SAMPLING; SCORING SYSTEM; SOCIAL BEHAVIOR; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VASCULAR DISEASE; WHITE MATTER;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CHOLINESTERASE INHIBITORS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; HYPERTENSION; MALE; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 23644456859     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.1331     Document Type: Article

References (29)

1. Amar K, Lewis T, Wilcock GK. 1995. The relationship between white matter low attenuation on brain CT and vascular risk factors: a memory clinic study. Age Ageing 24: 411-415.
2. Amar K, Bucks RS, Lewis T, et al. 1996. The effect of white matter low attenuation on cognitive performance in dementia of the Alzheimer type. Age Ageing 25: 443-448.
3. Connelly PJ, Prentice NP, Fowler KG. 2005. Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry 76: 320-324.
4. Connelly PJ, Prentice NP. 2005. Current smoking and response to cholinesterase inhibitors in Alzheimer's disease. Dement Geriatr Cogn Disord 19: 11-15.
5. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group. 1998. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartarate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1: 55-65.
6. Erkinjuntti T, Kurz A, Gauthier S, et al. 2002a. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 359: 1283-1290.
7. Erkinjuntti T, Skoog I, Lane R, Andrews C. 2002b. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Int J Clin Pract 56: 791-796.
8. Feldman H, Gauthier S, Hecker J, et al. 2003. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 51: 737-744.
9. Folstein MF, Folstein SE, McHugh PA. 1975. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
10. Gelinas I, Gauthier L, McIntyre M, et al. 1999. Development of a functional measure for persons with Alzheimer's disease: the Disability Scale for Dementia. Am J Occup Ther 53: 471-481.
11. George AJ, deLeon MJ, Gentes CI, et al. 1986. Leukoencephalopathy in normal and pathologic aging I: computed tomography of brain lucencies. Am J Neuroradiol 7: 561-566.
12. Iverson GL. 1998. Interpretation of Mini-Mental State Examination scores in community-dwelling elderly and geriatric neuropsychiatry patients. Int J Geriatr Psychiatry 13: 661-666.
13. Knopman D, Boland LL, Mosley T, et al. (Atherosclerosis Risk in Communities (ARIC) Study Investigators) 2001. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 56: 42-48.
14. Kumar V, Anand R, Messina J, et al. 2000. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 7: 159-169.
15. Kurz A, Erkinjuntti T, Bullock R, et al. 2003. Long-term safety and efficacy of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease: an interim analysis. Poster presented at the 16th Annual Meeting of the American Association for Geriatric Psychiatry (AAGP), Waikiki, Hawaii, 1-4 March 2003.
16. Launer LJ, Webster Ross G, Petrovitch H, et al. 2000. Mid-life blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging 21: 49-55.
17. Leys D, Soetaert G, Petit H, et al. 1990. Periventricular and white matter magnetic resonance imaging hyperintensities do not differ between Alzheimer's disease and normal aging. Arch Neurol 47: 524-527.
18. McKhann G, Drachman D, Folstein M, et al. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Task Force in Alzheimer's disease. Neurology 34: 939-944.
19. Rezek DL, Morris JC, Fulling KH, Gado MH. 1987. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology 37: 1365-1368.
20. Rosen WG, Terry RD, Fuld PA, et al. 1980. Pathological verification of ischaemic score in differentiation of dementias. Ann Neurol 7: 486-488.
21. Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. 1999. Efficacy and safty of Rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Br Med J 318: 633-640.
22. Skoog I, Lernfelt B, Landahl S, et al. 1996. A 15-year longitudinal study of blood pressure and dementia. Lancet 347: 1141-1145.
23. Snowdon D, Greiner L, Mortimer J, et al. 1997. Brain infarction and the clinical expression of Alzheimer's disease. JAMA 277: 813-817.
24. Sparks DL, Liu H, Scheff SW, et al. 1993. Temporal sequence of plaque formation in the cerebral cortex of non-demented individuals. J Neuropathol Exp Neurol 52: 135-142.
25. Sparks DL, Scheff SW, Liu H, et al. 1995. Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci 131: 162-169.
26. Spiegel R, Brunner C, Ermini-Funfschilling D, et al. 1991. A new behavioural assessment scale for geriatric out- and in-patients: the NOSGER (Nurses Observation Scale for Geriatric Patients). J Am Geriatr Soc 39: 339-347.
27. Tarvonen-Schröeder S, Röyttä M, Räihä I, et al. 1996. Clinical features of leuko-araiosis. J Neurol Neurosurg Psychiatry 60: 431-436.
28. Wechsler D. 1981. Wechsler Adult Intelligence Scale-Revised. The Psychological Corporation: New York.
29. Wilcock GK, Lilienfeld S, Gaens E. 2000. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 321: 1445-1449.